We have developed a radioligand receptor assay (RRA) with sufficient sensitivity and specificity for quantifying follitropin (FSH) in unextracted serum samples. Standard curves prepared by adding pituitary FSH to either buffer or gonadotropin-free serum were parallel and statistically indistinguishable in this assay, whereas gonadotropinfree serum alone had no activity. Cross-reactivity with related pituitary hormones was negligible. Pituitary FSH was calibrated with commonly used reference preparations so that RRA results could be compared with AlA results for identical standards. The patterns in daily blood samples in six normal menstrual cycles were similar by both methods. The mean RIA:RIA ratio in both the follicular and luteal phases was between 0.6 and 0.7, and at mid-cycle decreased to 0.48, suggesting an alteration of isohormone composition at mid-cycle. In 27 women with premature ovarian failure, RRA:RIA ratios ranged from below the RRA minimum detectable dose to 4.6, suggesting that immunoreactive FSH might not be capable of binding to the FSH receptor in some patients, whereas in patients with high RRA:RIA ratios, circulating inhibitors of FSH receptor binding might be present and perhaps contributing to the observed ovarian failure. Use of this RRA in conjunction with RIA and in vitro bioassays may better define the relative contribution of FSH isohormones, autocrine or paracrine modulators of FSH bioactivity, and FSH-receptor binding competitors to the "total FSH biological signal" as detected by the gonadal FSH receptor.
We have developed a radioligand receptor assay (RRA) with sufficient sensitivity and specificity for quantifying follitropin (FSH) in unextracted serum samples. Standard curves prepared by adding pituitary FSH to either buffer or gonadotropin-free serum were parallel and statistically indistinguishable in this assay, whereas gonadotropinfree serum alone had no activity. Cross-reactivity with related pituitary hormones was negligible. Pituitary FSH was calibrated with commonly used reference preparations so that RRA results could be compared with AlA results for identical standards. The patterns in daily blood samples in six normal menstrual cycles were similar by both methods. The mean RIA:RIA ratio in both the follicular and luteal phases was between 0.6 and 0.7, and at mid-cycle decreased to 0.48, suggesting an alteration of isohormone composition at mid-cycle. In 27 women with premature ovarian failure, RRA:RIA ratios ranged from below the RRA minimum detectable dose to 4.6, suggesting that immunoreactive FSH might not be capable of binding to the FSH receptor in some patients, whereas in patients with high RRA:RIA ratios, circulating inhibitors of FSH receptor binding might be present and perhaps contributing to the observed ovarian failure. Use of this RRA in conjunction with RIA and in vitro bioassays may better define the relative contribution of FSH isohormones, autocrine or paracrine modulators of FSH bioactivity, and FSH-receptor binding competitors to the "total FSH biological signal" as detected by the gonadal FSH receptor.
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The use of radioimmunoassay (RIA) for determining concentrations of follitropin (FSH) in serum samples has greatlyfacilitated our understanding of the physiology and pathophysiology of reproduction.3However, (4, 5) as well as serum (6) . These factorscan have either agonist or antagonist activities, and may not always be detectedby FSH-specific RIAs (4) . Autoantibodies to the FSH receptorcould alsocontributeto assay differences, as we!! as to ovarian pathophysiology (7-9).
Thus, alternative assay systems were developed to more accurately quantify FSH biopotency (10) . When applied to serum samples, however, early assays were of little use, because of insufficient sensitivity or interferencefrom unidentified substances (6, 10) .
Improved in vitro bioassays with cultured rat granu-!osa cells (11) or immature rat Sertoli cells (12) have afforded sufficient sensitivity and specificity forquantitativeanalysis of bioactive FSH in human serum samples.Adverse effects of serum on these cultured cells were circumvented by precipitatinginterferingsubstanceswith polyethyleneglyco!(PEG) (13) or by using very small samples (12). Both kinds ofassay used target cellsteroidogenesis to index the responsesto FSH in the samples. However, the cellsused in these assays have alsobeen shown to respond to factorsthat modulate the steroidogenicresponse to FSH, including growth factors, activin, and inhibin (14) (15) (16) (17) , such that the steroidogenic response measured after serum sample ap- 
Materials and Methods Radioimmunoassay
The Sigma), incubating at room temperature for30 mm, and centrifugingat 5000 x g in a Model J6-B centrifuge (Beckman Instruments, Brea, CA) for 40 mm. We then aspirated the samples and counted the radioactivity remaining in the tubes. Nonspecific binding (NSB) was determined by adding 250 ng of NIH-FSH-I-3 per tube. The 2nd IRP-HMG standard was used to calibrate the RRA so that FSH concentrations in patients' samples could be compared directly in the RRA and RIA. Additional standards used to calibrate this assay include the 2nd IRP-Pituitary (WHO 78/549) and LER-907, both of which were generously provided by the Hormone Distribution Program of the NIADDK, as were the LH, thyrotropin, and human choriogonadotropin used for the specificity studies.
Samples
Serum samples obtained daily from six normally cycling volunteers were assayed in duplicate by RRA, and compared with determinations by RIA as previously described (27) . The results for both RIA and RRA were aligned by using as day 0 the day of the LH peak (as previously determined by RIA) (27) . Post-menopausal samples were selected on the basis of age (>50 years) and the lack of other endocrine disorders or medication. Gonadotropin-free serum was obtained from gonadoliberin-deficient men with no detectable LH or FSH by RIA.
The concentration of FSH in serum samples from 27 patients with POF was determined by RIA and RRA. Criteria for POF diagnosis included onset of amenorrhea before the age of 40 years, increased concentrations of immunoactive gonadotropins (>40 mt. units/L for FSH and LH), and decreased concentrations of estradiol (<74 pmollL) (18) (19) (20) (21) . Patients with chromosomal abnormalities were excluded from this study. Five of the 27 patients studied were diagnosed with other endocrine deficiencies, including hyperthyroidism, adrenal insufficiency, and (or) diabetes mellitus. One of these patients also had autoantibodies to three endocrine glands. Three patients had primary amenorrhea. Eleven of the POF patients had had one to four pregnancies.
Data Analysis
Inhibition curves generated with various standards were analyzed for slope and effective dose (ED) by use of the NIHRJA computer program (28) . Al! assays included standards prepared either in buffer or gonadotropin-free serum, and patients' sample data were interpolated from the serum standard curve, although the 
Results

RRA Characterization
Inhibition curves obtained by adding increasing quantitiesof FSH to bufferor gonadotropin-freeserum from a typicalassay are compared in Figure 1 . There was no significant difference between bufferand serum curves in either slope (0.99 ± 0.06 vs 0.91 ± 0.05, respectively) or ED50 (2.05 ± 0.12 vs 2.0 ± 0.18 ng, respectively). Linear-regression analysis comparing the two inhibition curves indicated a correlation coefficient (r) of 0.98 (P <0.0001). Gonadotropin-free serum alone showed no activity up to 150 pL, indicating that the assay is not susceptible to nonspecific interference by addition of serum. The MDD over six consecutive assays The specificity ofthe assay was assessed in relation to other gonadotropins (Table 1) .These resultswere calculated at the ED50 dose for LH and thyrotropin, a!-though the curves were not parallelto the FSH standard. Only slight inhibition was observed for choriogonadotropin at a dose of 2.5 pg, a dose roughly 2500-fold greater than that of the radioligand.
Assay of Serum Samples
To assess the utility of this RRA for quantifying FSH in serum under physiological conditions, we compared RIA and RRA potencies in daily samples from six normal menstrual cycles. Mean FSH values for all six cycles, aligned to the mid-cycle LH surge, are shown in Figure 3 . Values below the MDD for the particular assay in which a cycle was analyzed were not included in calculating the means. Similarly, no data points below the mean MDD were used for RRA:RIA ratio calculations. In general, FSH quantities determined by RRA were less than RIA values, but the overall pattern was quite similar. As shown in Table 2 , RRA:RIA ratios for the early follicular, late follicular, and luteal phases Normalfollicular-phase ratios are derived from data in Fig. 3 ratiosranged from 1.1 to 4.69,indicatingthat something in the serum from these patients was able to inhibit binding of radiolabeled FSH to its receptor but was not immunoactive in our dimer-specific FSH RIA.
Because this RIA has been extensivelyvalidated for quantification of FSH in serum from normal and pathophysiological patients,the factor(s) modulating FSH binding to receptorare not likely to be pituitaryFSH.
Discussion
We have developed an RRA with sufficient sensitivity and specificity for quantifying FSH in human serum samples without extractionor dialysis. We observed no inhibitionof radioligandbinding by gonadotropin-free serum, and the standard curves prepared by adding hFSH to eitherbuffer or gonadotropin-free serum was statistically indistinguishable. Thus, this RRA is not affectedby "nonspecific" serum factorsthat have hampered previous receptor assays (29). The increase in sensitivity and specificity for serum FSH is due to the use of purified membrane fractions containing FSH receptors (26), as well as to purification of the radioligand by po!yacrylamide gel electrophoresis, which has been shown previouslyto remove radiolabeledsubunits and impurities after lactoperoxidase iodination (25).
Use of less-purified membrane fractionsreduces the sensitivity for serum FSH by at leastfivefold (30, 31) . Electrophoresis-purified radioligand also contributes to the reduction of cross-reactivity with relatedglycoprot.ein hormones to amounts consistentwith the FSH contamination known to be present in these preparations; thisdegree of cross-reactivity should not interfere with the accuracy of FSH determinations under most physiological conditions.
When applied to analysis of daily serum samples obtained from sixnormal menstrual cycles, RRA values were generally lower than those by RIA, but followed similarpatterns.
Although not statistically significant, the greatest deviationwithin the cycleoccurred on the day of the mid-cycle LH surge, where FSH concentrationsby RR.A were consistently lessthan halfofthe RIA were equal to or lessthan those in the early follicular phase when analyzed by RRA, whereas by RIA the mid-cycle values were greater.
The mean FSH concentrationsin normal females are closeto,or occasionallybelow, the MDD of this RRA, thereby limitingitsutility fornormal basal FSH analyses,especially in the lutea!phase. Use of biosynthetically'produced receptors at greater densities(higher specificactivity)may allow further improvement in assay sensitivity such that the RRA could then be of wide utility forthe study of normal FSH physiology.
At present,however, the greatest potential application of this assay is for analysis of physiological or pathophysiologica! states in which serum concentrations of FSH are increased, e.g., in menopause and POF. In this study of 27 POF patients,results for seven patients(POF Group I)suggest that the immunoactive FSH in these patients did not bind to receptorsand hence did not appear to be biologically active.To the extent thatthisaberrant form ofFSH contributestothe lack of ovarian response,these patientsmight respond favorablyto the administrationof exogenous FSH. On the other hand, sixpatients(POF Group Ill)had ratios greater than mean ±2 SD for a!! the POF patients, suggesting that something in the serum of these patients was inhibiting the binding of FSH to its receptor, thereby producing above-norma! RRA values forFSH in the absence of ovarian response.Such inhibitors might include autoantibodies to the FSH receptor (7) (8) (9) or circulating FRBCs similar to those described in follicular fluid (4, 22, 32, 33) . Although further study is required to determine the nature ofthe agent(s)responsiblefordifferences in RRA and RIA estimationsofFSH concentration,resultsof thisstudy are consistent with the hypothesis that POF represents a disease state with various etiologies, some of which may be related to abnormal FSH action,whereas others might be independent of FSH concentrations. In studying POF, it is clinically important when designing treatment to distinguish total immunoactive FSH from the various potentialmodulators of FSH action that together comprise the total FSH "signal." For example, this ERA would be of use in screeningPOF patients for potential
FRBCs that might be inhibitingthe activity of endogenous FSH. Once identified, such factors could be analyzedby bioassaytodetermine theireffect on the overall FSH biological signal(e.g., agonist or antagonist), and treatments developed to suppress theiractivity.
Several in vitro bioassays have been developed and validatedfor quantifying FSH in serum. In one assay (11) , whereas that observed with the RRA isalways <1 over the menstrual cycle. The Sertoli cell bioassay showed a B:I ratio >1 when NIH-FSH-I-2 was the standard, but thisratiodecreased to <1 when the NIH-FSH-I-3 standard was used (12), as was used in both the GAB assay and the ERA described here; this suggests that the compositions of the two standards differ. Because the RIAs used for comparison with either bioassay or the RRA are not identical, we cannot determine whether differences in B:! ratiosof the three assays are due to differences in sensitivity to FSH isohormones in the bioassays and receptor assays, or to differences in FSH isohormone recognition by the antibodies used in the respective immunoassays.
However, there are also differences in B:! ratios across the menstrual cycle between assays, which suggests that the assays may recognize different subsets of circulating FSH. For example, the lowest B:! ratio observed with the GAB bioassay (11) and the ERA is at mid-cycle (1.4 and 0.48, respectively), the point at which the maximal B:! ratio (2.21)was observed with the Sertoli cell bioassay (12). The cause of this discrepancy cannot be determined from these data, but may be due to differential sensitivityofthe Sertoli cell bioassay to other serum factors that modulate cellular response to FSH, but do not act through the FSH receptor, such as insulin-like growth factor(!GF-1)(14, 15). Such factorsmay be removed by the PEG pretreatment used in the GAB bioassay, thereby explaining why the GAB and receptor assays agree at this point.Another consistentfeature of all these assays is that the ratioobserved for post-menopausal patientsissimilartothe overallB:!or RRA:RIA ratio observed through the follicular and luteal phases of the menstrual cycle. Because the goal of developing RRAs or bioassaysto quantify FSH in serum is to more accuratelyestimate the total FSH biological "signal" experienced by the gonadal FSH receptor,the most judicious approach might be to combine all three assay systems. In this way, the relative contribution of FSH, FSH isohormones, modulators of FSH biological action, and FRBCs to normal reproductive physiology, as well as to reproductivedisorders, might be betterdiscerned.
